Federal Jury Rules In Favor Of Covidien In Patent Litigation Trial

Main Category: Medical Malpractice / Litigation
Also Included In: Clinical Trials / Drug Trials
Article Date: 25 Feb 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Covidien Ltd. (NYSE: COV; BSX: COV) today announced that a federal jury has ruled in favor of the Company in the patent litigation case Applied Medical Resources Corp. v. United States Surgical. The jury ruled that United States Surgical, a Covidien subsidiary, does not infringe Applied Medical's U.S. Patent No. 5,385,553 related to trocar seal technology.

"We are very pleased with the jury's verdict and look forward to continuing to provide innovative surgical instruments to our customers," said Scott Flora, President, Surgical Devices, Covidien.

About Covidien Ltd.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 43,000 employees worldwide in 57 countries, and its products are sold in over 130 countries.

http://www.covidien.com